Abstract
This paper illustrates possible changes in revenue from league drug policies. We argue that there were perceived financial incentives for Major League Baseball (MLB) to not have a steroid policy. MLB did not begin testing players for steroids in earnest until the 2005 season although the league office acknowledged use a decade and a half earlier. Only after outside pressure did the league implement a policy with specific, enforceable penalties. This paper uses regression analysis to assess whether the absence of a true steroid policy prior to 2005 affected scoring, then quantifies the amount of revenue baseball owners lost as a consequence of the updated steroid policy.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call